Physician profile
James E Segal
NPI 1215939855
$1,957.27
in general payments reported to CMS, 2019-2025
26 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $48.53 · 2021: $71.43 · 2022: $168 · 2023: $566 · 2024: $470 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $266.02 | 2022-2025 | |
| Abbvie INC. | $240.90 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $181.83 | 2023-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $121.63 | 2022-2023 | Ova1 |
| Hologic Sales and Service, LLC | $115.72 | 2023-2024 | Acessa Provu System, Aptima, Omni Hysteroscope |
| Amgen INC. | $113.25 | 2019-2024 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $103.88 | 2022-2023 | |
| Organon LLC | $100.17 | 2023-2025 | Nexplanon, Jada System |
| Biogen, INC. | $84.97 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $83.06 | 2023-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $68.69 | 2019-2024 | |
| Channel Medsystems, INC. | $68.63 | 2023 | |
| Shield Therapeutics INC | $53.56 | 2025 | |
| Meditrina | $52.08 | 2023-2025 | |
| Ascend Therapeutics US, LLC | $51.72 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $38.56 | 2024-2025 | Myfembree |
| Daiichi Sankyo INC. | $35.11 | 2019 | |
| Coopersurgical, INC. | $30.62 | 2019-2023 | Paragard T 380a |
| Sanofi Pasteur INC. | $28.82 | 2025 | |
| Allergan, INC. | $28.14 | 2019 | |
| Evofem Biosciences, INC. | $24.18 | 2020-2021 | |
| Gynesonics, INC. | $13.39 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Therapeuticsmd, INC. | $13.30 | 2019 | |
| Agile Therapeutics, INC. | $13.28 | 2022 | |
| Avion Pharmaceuticals | $13.01 | 2023 | Balcoltra |
| Mission Pharmacal Company | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.